Primary screening for human papillomavirus compared with cytology screening for cervical cancer in European settings: Cost effectiveness analysis based on a Dutch microsimulation model

BMJ (Online)

Volumn 344, Issue 7847, 2012, Pages

  De Kok, Inge M C M ^a   Van Rosmalen, Joost ^a   Dillner, Joakim ^b   Arbyn, Marc ^c   Sasieni, Peter ^d   Iftner, Thomas ^e   Van Ballegooijen, Marjolein ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b LUND UNIVERSITY   (Sweden)

^c SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^e UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER RISK; COMPARATIVE STUDY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CYTOLOGY; EUROPE; HEALTH CARE POLICY; INTERMETHOD COMPARISON; LIFESPAN; NETHERLANDS; PAPILLOMAVIRUS INFECTION; PREVALENCE; PRIORITY JOURNAL; QUALITY CONTROL; QUALITY OF LIFE; RISK ASSESSMENT; SCREENING TEST; SENSITIVITY ANALYSIS; SIMULATION; UTERINE CERVIX CANCER; ALPHAPAPILLOMAVIRUS; COMPUTER SIMULATION; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; HUMAN; ISOLATION AND PURIFICATION; SENSITIVITY AND SPECIFICITY; STATISTICAL MODEL; UTERINE CERVIX TUMOR; VAGINA SMEAR; VIROLOGY;

ALPHAPAPILLOMAVIRUS; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; EUROPE; FEMALE; HUMANS; MODELS, ECONOMIC; NETHERLANDS; PAPILLOMAVIRUS INFECTIONS; SENSITIVITY AND SPECIFICITY; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 84858067300     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.e670     Document Type: Article

References (45)

1. Bray F, Loos AH, McCarron P, Weiderpass E, Arbyn M, Moller H, et al. Trends in cervical squamous cell carcinoma incidence in 13 European countries: changing risk and the effects of screening. Cancer Epidemiol Biomarkers Prev 2005;14:677-86. (Pubitemid 40489214)
2. Karim-Kos HE, de Vries E, Soerjomataram I, Lemmens V, Siesling S, Coebergh JW. Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s. Eur J Cancer 2008;44:1345-89.
3. Arbyn M, Raifu AO, Weiderpass E, Bray F, Anttila A. Trends of cervical cancer mortality in the member states of the European Union. Eur J Cancer 2009;45:2640-8.
4. Arbyn M, Raifu AO, Autier P, Ferlay J. Burden of cervical cancer in Europe: estimates for 2004. Ann Oncol 2007;18:1708-15. (Pubitemid 47506260)
5. Levy-Bruhl D, Bousquet V, King LA, O'Flanagan D, Bacci S, Lopalco PL, et al. The current state of introduction of HPV vaccination into national immunisation schedules in Europe: results of the VENICE 2008 survey. Eur J Cancer 2009;45:2709-13.
6. Hildesheim A, Herrero R, Wacholder S, Rodriguez AC, Solomon D, Bratti MC, et al. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA 2007;298:743-53. (Pubitemid 47263157)
7. Stoler MH, Schiffman M. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. JAMA 2001;285:1500-5. (Pubitemid 32221899)
8. Arbyn M, Sasieni P, Meijer CJ, Clavel C, Koliopoulos G, Dillner J. Clinical applications of HPV testing: a summary of meta-analyses. Vaccine 2006;24(suppl 3):S3/78-89.
9. Cuzick J, Clavel C, Petry KU, Meijer CJ, Hoyer H, Ratnam S, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 2006;119:1095-101. (Pubitemid 44116919)
10. Dillner J, Rebolj M, Birembaut P, Petry KU, Szarewski A, Munk C, et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ 2008;337:a1754.
11. Hoyer H, Scheungraber C, Kuehne-Heid R, Teller K, Greinke C, Leistritz S, et al. Cumulative 5-year diagnoses of CIN2, CIN3 or cervical cancer after concurrent high-risk HPV and cytology testing in a primary screening setting. Int J Cancer 2005;116:136-43. (Pubitemid 40827767)
12. Petry KU, Menton S, Menton M, van Loenen-Frosch F, de Carvalho Gomes H, Holz B, et al. Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients. Br J Cancer 2003;88:1570-7. (Pubitemid 36713784)
13. Sherman ME, Lorincz AT, Scott DR, Wacholder S, Castle PE, Glass AG, et al. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst 2003;95:46-52. (Pubitemid 36124295)
14. Coupe VM, de Melker HE, Snijders PJ, Meijer CJ, Berkhof J. How to screen for cervical cancer after HPV16/18 vaccination in the Netherlands. Vaccine 2009;27:5111-9.
15. Naucler P, Ryd W, Tornberg S, Strand A, Wadell G, Elfgren K, et al. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. J Natl Cancer Inst 2009;101:88-99.
16. Rebolj M, van Ballegooijen M, Berkers LM, Habbema D. Monitoring a national cancer prevention program: successful changes in cervical cancer screening in the Netherlands. Int J Cancer 2007;120:806-12. (Pubitemid 46175400)
17. Dutch Society for Pathology. Guideline draft 2.0. Quality assurance of cytopathological investigation of the cervix. [In Dutch.] NVVP, 2006.
18. Rebolj M, Bais AG, van Ballegooijen M, Boer R, Meerding WJ, Helmerhorst TJ, et al. Human papillomavirus triage of women with persistent borderline or mildly dyskaryotic smears: comparison of costs and side effects of three alternative strategies. Int J Cancer 2007;121:1529-35. (Pubitemid 47328712)
19. Habbema JD, van Oortmarssen GJ, Lubbe JT, van der Maas PJ. The MISCAN simulation program for the evaluation of screening for disease. Comput Methods Programs Biomed 1985;20:79-93. (Pubitemid 16217562)
20. CBS (Netherlands Central Bureau of Statistics). Death by cause of death, age and sex 1950-1992. CBS, 1994.
21. SIG (Information Centre for Health Care). Hospital diagnosis statistics 1963-1985. SIG, 1985.
22. Van Ballegooijen M. Effects and costs of cervical cancer screening. [Thesis, 1998.]
23. Van Oortmarssen GJ, Habbema JD. Epidemiological evidence for age-dependent regression of pre-invasive cervical cancer. Br J Cancer 1991;64:559-65.
24. Bulk S, Bulkmans NW, Berkhof J, Rozendaal L, Boeke AJ, Verheijen RH, et al. Risk of high-grade cervical intra-epithelial neoplasia based on cytology and high-risk HPV testing at baseline and at 6-months. Int J Cancer 2007;121:361-7. (Pubitemid 46917706)
25. Berkhof J, de Bruijne MC, Zielinski GD, Meijer CJ. Natural history and screening model for high-risk human papillomavirus infection, neoplasia and cervical cancer in the Netherlands. Int J Cancer 2005;115:268-75. (Pubitemid 40586736)
26. Van Ballegooijen M, Rebolj M, Essink-Bot ML, Meerding WJ, Berkers LM, Habbema JDF. De effecten en kosten van het bevolkingsonderzoek naar baarmoederhalskanker in Nederland na de herstructurering. Erasmus MC, afdeling Maatschappelijke Gezondheidszorg, 2006.
27. Goldie SJ, Kohli M, Grima D, Weinstein MC, Wright TC, Bosch FX, et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 2004;96:604-15. (Pubitemid 38584984)
28. Mandelblatt JS, Lawrence WF, Womack SM, Jacobson D, Yi B, Hwang YT, et al. Benefits and costs of using HPV testing to screen for cervical cancer. JAMA 2002;287:2372-81. (Pubitemid 34493200)
29. Berkhof J, Coupe VM, Bogaards JA, van Kemenade FJ, Helmerhorst TJ, Snijders PJ, et al. The health and economic effects of HPV DNA screening in the Netherlands. Int J Cancer 2010;127:2147-58.
30. Cantor SB. Cost-effectiveness analysis, extended dominance, and ethics: a quantitative assessment. Med Decis Making 1994;14:259-65. (Pubitemid 24206351)
31. Ronco G, van Ballegooijen M, Becker N, Chil A, Fender M, Giubilato P, et al. Process performance of cervical screening programmes in Europe. Eur J Cancer 2009;45:2659-70.
32. Lynge E, Rebolj M. Primary HPV screening for cervical cancer prevention: results from European trials. Nat Rev Clin Oncol 2009;6:699-706.
33. Karim-Kos HE, de Vries E, Soerjomataram I, Lemmens V, Siesling S, Coebergh JW. Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s. Eur J Cancer 2008;44:1345-89.
34. OECD. Unit labour costs-annual indicators. 2010. www.oecd.org.
35. Kim JJ, Wright TC, Goldie SJ. Cost-effectiveness of human papillomavirus DNA testing in the United Kingdom, the Netherlands, France, and Italy. J Natl Cancer Inst 2005;97:888-95. (Pubitemid 41417940)
36. Mittendorf T, Petry KU, Iftner T, Greiner W, von der Schulenburg JM. Economic evaluation of human papillomavirus screening in Germany. Eur J Health Econ 2003;4:209-15. (Pubitemid 37247973)
37. Sherlaw-Johnson C, Philips Z. An evaluation of liquid-based cytology and human papillomavirus testing within the UK cervical cancer screening programme. Br J Cancer 2004;91:84-91. (Pubitemid 39013049)
38. Goldie SJ, Kim JJ, Wright TC. Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more. Obstet Gynecol 2004;103:619-31. (Pubitemid 40459019)
39. Wright TC Jr, Schiffman M, Solomon D, Cox JT, Garcia F, Goldie S, et al. Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. Obstet Gynecol 2004;103:304-9.
40. Goldhaber-Fiebert JD, Stout NK, Salomon JA, Kuntz KM, Goldie SJ. Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination. J Natl Cancer Inst 2008;100:308-20. (Pubitemid 351480523)
41. Zhao FH, Lin MJ, Chen F, Hu SY, Zhang R, Belinson JL, et al. Performance of high-risk human papillomavirus DNA testing as a primary screen for cervical cancer: a pooled analysis of individual patient data from 17 population-based studies from China. Lancet Oncol 2010;11:1160-71.
42. Van Ballegooijen M, Boer R, van Oortmarssen GJ, Koopmanschap MA, Lubbe JTHN, Habbema JDF. Cervical cancer screening: age ranges and intervals. An updated cost-effecitiviteitsanalyse. [In Dutch.] Instituut Maatschappelijke Gezondeheidszorg, Erasmus University Rotterdam, 1993.
43. Gustafsson L, Ponten J, Bergstrom R, Adami HO. International incidence rates of invasive cervical cancer before cytological screening. Int J Cancer 1997;71:159-65. (Pubitemid 27252984)
44. Van Rosmalen J, de Kok IM, van Ballegooijen M. Cost-effectiveness of cervical cancer screening: cytology versus human papillomavirus DNA testing. BJOG 2012; published online 18 Jan.
45. Siegel JE, Weinstein MC, Russell LB, Gold MR. Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. JAMA 1996;276:1339-41. (Pubitemid 26346934)